Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

ASCO 2021: 2-Year Follow-up With Nivolumab/Ipilimumab Plus Chemotherapy for Advanced Lung Cancer
Robotic Bronchoscopy May Improve Timing and Accuracy of Lung Cancer Diagnosis
ASCO 2021: Video-Assisted Thoracoscopy Versus Open Lobectomy for Early-Stage Lung Cancer
$20 Million Donation to MSK to Support Lung Cancer Research
ASCO 2021: Subgroup Efficacy Analysis of Sotorasib for Advanced KRAS G12C–Mutated NSCLC
ASCO 2021: Surgical Outcomes With Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC
Anti–PD-1 Monoclonal Antibody Plus Chemotherapy for Advanced Squamous NSCLC
Sotorasib Receives Approval for NSCLC With KRAS G12C Mutations
FDA Accepts Submission for Sintilimab in Combination With Pemetrexed/Platinum Chemotherapy in NSCLC
Does Performance Status Correlate With Survival in Pembrolizumab-Treated Patients With NSCLC?
FDA Approves Targeted Therapy Amivantamab-vmjw for Subset of NSCLC
ASCO 2021: Atezolizumab in Early-Stage Resected NSCLC After Chemotherapy
RATIONALE 303 Update on Tislelizumab Versus Docetaxel in Advanced NSCLC
Priority Review Granted by FDA for Mobocertinib in Subtype of NSCLC
AACR 2021: Influence of Aneuploidy on Response to Immunotherapy for Lung Cancer
AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC
EGFR Inhibitor Mefatinib Under Study in Advanced EGFR-Mutant NSCLC
Brigatinib in Alectinib-Resistant ALK-Positive NSCLC
Updated USPSTF Recommendation on Lung Cancer Screening
Novel Bispecific PD-L1 and CTLA-4 Antibody for Metastatic NSCLC
Tyrosine Kinase Inhibitor Combination Therapy for HER2-Mutated NSCLC
Cemiplimab-rwlc Monotherapy and PD-L1 Expression in Advanced NSCLC
Do Tailored Chemotherapy Regimens Improve Outcomes in Early-Stage NSCLC?
FDA Expands Approval of Lorlatinib for ALK-Positive Non–Small Cell Lung Cancer
Tyrosine Kinase Inhibitor Therapy for Stage III EGFR-Mutated NSCLC
WCLC 2020: 3-Year Survival Update on Pembrolizumab for Locally Advanced or Metastatic NSCLC
WCLC 2020: 5-Year Survival Update on Pembrolizumab Versus Docetaxel in NSCLC
FDA Approves Cemiplimab-rwlc and Expands Approval of Companion Diagnostic in NSCLC
WCLC 2020: Pembrolizumab Plus Chemotherapy for Metastatic NSCLC
Sotorasib Receives FDA Priority Review for KRAS G12C–Mutated Advanced Lung Cancer
WCLC 2020: KEYNOTE-799 Update on Pembrolizumab With Chemoradiotherapy in Stage III Lung Cancer
WCLC 2020: Updated Overall Survival With Atezolizumab in NSCLC From IMpower110
WCLC 2020: Patient-Reported Outcomes With Lorlatinib Versus Crizotinib in ALK-Positive NSCLC
WCLC 2020: Genomic Analysis of Women With Lung Cancer Who Never Smoked
WCLC 2020: Adding Ipilimumab to Pembrolizumab for Metastatic NSCLC
Tepotinib Granted Accelerated Approval by FDA in Metastatic NSCLC
WCLC 2020: Small-Molecule Inhibitor Active in KRAS G12C–Mutated NSCLC
WCLC 2020: Novel Tyrosine Kinase Inhibitor Versus Chemotherapy for EGFR-Mutated NSCLC
Outcomes With Durvalumab After Chemoradiotherapy for NSCLC
JAVELIN Medley VEGF: Monoclonal Antibody Plus VEGFR Inhibitor Studied in NSCLC
FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers
Biomarker May Predict Susceptibility to Radiation Pneumonitis in Patients With Lung Cancer
Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC
Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?
Lorlatinib Receives Priority Review in Untreated ALK-Positive Lung Cancer
Adjuvant Osimertinib Approved by FDA for EGFR-Mutated Lung Cancer
Individualized Versus Standard Dosing of Radiotherapy in Stage III NSCLC


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.